Zoetis Inc. (ZTS)
Zoetis (ZTS) Beats Q4 Earnings and Revenue Estimates
Zoetis (ZTS) came out with quarterly earnings of $1.48 per share, beating the Zacks Consensus Estimate of $1.4 per share. This compares to earnings of $1.4 per share a year ago.
Zoetis Gears Up to Report Q4 Earnings: Here's What to Expect
ZTS is set up for Q4 earnings beat, fueled by strong international companion animal products sales, even as weaker U.S. demand weighs on results.
Curious about Zoetis (ZTS) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of Zoetis (ZTS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Zoetis (ZTS) Expected to Beat Earnings Estimates: Should You Buy?
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Zoetis (ZTS) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Zoetis (ZTS) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zoetis (ZTS) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zoetis: Undervalued And Oversold
Zoetis, the global animal health leader, is deeply undervalued at a 19x forward P/E versus its 10-year average of 31.8x. ZTS is positioned to benefit from the secular trend of pet humanization, with 66% of revenue from companion animal products. Consensus expects 8.9% annual EPS growth and 9%-10% dividend growth, supporting a fair value estimate of $170 per share.
Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zoetis: Cheap Valuation And Attractive Product Launch Pipeline
I rate Zoetis (ZTS) a buy, citing a robust pipeline, upcoming product launches, and discounted valuation versus peers. ZTS targets new therapeutic white spaces—oncology, cardiology, and renal disease—minimizing risk and offering substantial first-mover advantages. The CKD monoclonal antibody for canine renal disease, launching in 2027, could unlock a $3–4 billion market with recurring revenue potential.
Zoetis (ZTS) Stock Dips While Market Gains: Key Facts
Zoetis (ZTS) reached $125.32 at the closing of the latest trading day, reflecting a -1.45% change compared to its last close.
Zoetis Inc. (ZTS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Zoetis Inc. (ZTS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
